MA34169B1 - Dérivés d'acide 1-amino-2-cyclopropyléthylboronique - Google Patents

Dérivés d'acide 1-amino-2-cyclopropyléthylboronique

Info

Publication number
MA34169B1
MA34169B1 MA35323A MA35323A MA34169B1 MA 34169 B1 MA34169 B1 MA 34169B1 MA 35323 A MA35323 A MA 35323A MA 35323 A MA35323 A MA 35323A MA 34169 B1 MA34169 B1 MA 34169B1
Authority
MA
Morocco
Prior art keywords
cyclopropylethylboronic
amino
acid derivatives
relates
compositions
Prior art date
Application number
MA35323A
Other languages
English (en)
Inventor
Paul E Fleming
Jing Li
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA34169B1 publication Critical patent/MA34169B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des nouveaux composés utiles comme inhibiteurs du protéasome. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention et des procédés employant les compositions dans le traitement de diverses maladies.
MA35323A 2010-03-31 2011-03-30 Dérivés d'acide 1-amino-2-cyclopropyléthylboronique MA34169B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31
PCT/US2011/030455 WO2011123502A1 (fr) 2010-03-31 2011-03-30 Dérivés d'acide 1-amino-2-cyclopropyléthylboronique

Publications (1)

Publication Number Publication Date
MA34169B1 true MA34169B1 (fr) 2013-04-03

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35323A MA34169B1 (fr) 2010-03-31 2011-03-30 Dérivés d'acide 1-amino-2-cyclopropyléthylboronique

Country Status (26)

Country Link
US (3) US8513218B2 (fr)
EP (1) EP2552216B1 (fr)
JP (1) JP5933523B2 (fr)
KR (1) KR20130036228A (fr)
CN (3) CN102892291A (fr)
AR (1) AR080863A1 (fr)
AU (1) AU2011235227B2 (fr)
CA (1) CA2794334C (fr)
CL (1) CL2012002733A1 (fr)
CO (1) CO6630162A2 (fr)
CR (1) CR20120529A (fr)
DO (1) DOP2012000257A (fr)
EA (1) EA029521B1 (fr)
EC (1) ECSP12012249A (fr)
MA (1) MA34169B1 (fr)
MX (1) MX2012011298A (fr)
NZ (1) NZ602622A (fr)
PE (1) PE20130383A1 (fr)
PH (1) PH12012501943A1 (fr)
RU (1) RU2012146101A (fr)
SG (1) SG184222A1 (fr)
TN (1) TN2012000465A1 (fr)
UA (1) UA110612C2 (fr)
UY (1) UY33314A (fr)
WO (1) WO2011123502A1 (fr)
ZA (2) ZA201207406B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453556C2 (ru) 2005-11-09 2012-06-20 Протеоликс, Инк. Соединения для ингибирования фермента
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
KR20170040374A (ko) 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CA2727862C (fr) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Composes de borates esters et compositions pharmaceutiques contenant des composes
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (fr) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Composes pour inhibition de l'immunoproteasome
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CA2807546C (fr) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Derives cycliques d'esters d'acide boronique et leurs utilisations therapeutiques
CA2855368A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite vis-a-vis d'inhibiteurs du proteasome
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
SG11201403254QA (en) * 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
JP6215235B2 (ja) 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
MX2016003979A (es) 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EP3139930B1 (fr) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Sels et polymorphes de dérivés cycliques d'ester d'acide boronique, et leurs utilisations thérapeutiques
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
WO2016003929A1 (fr) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
EP3193904B1 (fr) 2014-08-18 2025-10-01 Cornell University Dipeptidomimetiques en tant qu'inhibiteurs des immunoproteasomes humains
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102764027B1 (ko) 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
EP3589659B1 (fr) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinaisons pour utilisation dans le traitement du cancer
EP3694605A4 (fr) 2017-10-11 2021-10-27 Cornell University Inhibiteurs peptidomimétiques du protéasome
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
EP3781576B1 (fr) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (fr) 1992-08-14 1997-03-05 The Procter & Gamble Company Compositions détergents liquides contenant de l'acide borique
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
EP1017398A1 (fr) 1997-09-25 2000-07-12 Proscript, Inc. INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
CN1282242A (zh) 1997-12-16 2001-01-31 赛福伦公司 多相催化蛋白酶抑制剂用作抗肿瘤剂
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
WO2001002424A2 (fr) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
GEP20053504B (en) 2000-02-29 2005-05-10 Bristol Myers Squibb Co Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
HRP20212002T1 (hr) 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
US20090304631A1 (en) 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (fr) 2007-07-05 2009-01-08 Trustees Of Tufts College Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
AU2007357338B2 (en) 2007-08-06 2014-03-20 Takeda Pharmaceutical Company Limited Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CA2727862C (fr) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Composes de borates esters et compositions pharmaceutiques contenant des composes
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid

Also Published As

Publication number Publication date
KR20130036228A (ko) 2013-04-11
JP5933523B2 (ja) 2016-06-08
CN107266485A (zh) 2017-10-20
WO2011123502A1 (fr) 2011-10-06
MX2012011298A (es) 2012-11-06
US9023832B2 (en) 2015-05-05
ZA201308086B (en) 2015-03-25
CL2012002733A1 (es) 2013-01-25
UA110612C2 (uk) 2016-01-25
TN2012000465A1 (en) 2014-01-30
ZA201207406B (en) 2014-01-29
AU2011235227A1 (en) 2012-10-18
NZ602622A (en) 2015-01-30
CN106008570A (zh) 2016-10-12
EP2552216B1 (fr) 2018-01-24
CA2794334A1 (fr) 2011-10-06
ECSP12012249A (es) 2012-11-30
US20110245203A1 (en) 2011-10-06
JP2013523760A (ja) 2013-06-17
CN102892291A (zh) 2013-01-23
RU2012146101A (ru) 2014-05-10
US8513218B2 (en) 2013-08-20
CA2794334C (fr) 2018-06-12
PH12012501943A1 (en) 2017-08-23
PE20130383A1 (es) 2013-04-24
US20140011998A1 (en) 2014-01-09
EA029521B1 (ru) 2018-04-30
SG184222A1 (en) 2012-10-30
DOP2012000257A (es) 2012-11-15
CR20120529A (es) 2013-01-11
US20140179631A1 (en) 2014-06-26
US8703743B2 (en) 2014-04-22
EA201290980A1 (ru) 2013-03-29
EP2552216A4 (fr) 2013-07-31
EP2552216A1 (fr) 2013-02-06
AR080863A1 (es) 2012-05-16
AU2011235227B2 (en) 2016-09-08
UY33314A (es) 2011-10-31
CO6630162A2 (es) 2013-03-01

Similar Documents

Publication Publication Date Title
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
EA200870019A1 (ru) Лактамовые соединения и способы их применения
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA200802054A1 (ru) Ингибиторы фермента
EP2257161A4 (fr) Inhibiteurs de l'ahcy hydrolase destinés au traitement de l'hyper-homocystéinémie
MA35895B1 (fr) Inhibiteurs d'iap
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
EA201791321A1 (ru) Составы ингибитора lfa-1